Jump to the top of the page

Showing 690 – 700 of 1304 results

  • Robert Metzger

    View biography for Robert Metzger, Senior Director.

  • Cove Hill Partners and myDigitalOffice Transaction

    William Blair acted as the exclusive financial advisor to Cove Hill Partners in connection with its strategic investment in MyDigitalOffice Holdings, Inc.

  • G2V Group and Freshstream Investment Partners transaction

    William Blair acted as the exclusive financial advisor to G2V Group, in connection with its pending sale to Freshstream Investments Partners.

  • William Blair Investment Management Named a 2024 Best Place to Work

    For the 12th year, William Blair Investment Management was named a Best Place to Work in Money Management by Pensions & Investments magazine.

  • Stephanie Braming Named a Most Powerful Woman in Finance by American Banker

    Stephanie Braming, global head of William Blair Investment Management, was named a most powerful woman in finance by American Banker magazine.

  • Apellis Pharmaceuticals Inc Initiation

    William Blair initiated research coverage of Apellis Pharmaceuticals, Inc. (APLS $27.38), a global biopharmaceutical company focused on treating diseases by controlling the complement cascade.

  • Zeta Global Holdings Corp. Initiation

    William Blair initiated research coverage of Zeta Global Holdings Corp. (ZETA $7.99), a full stack enterprise marketing technology platform that helps businesses acquire, grow, and retain customers.

  • CarLotz Inc Initiation

    William Blair & Company initiated research coverage of CarLotz, Inc. (LOTZ $9.10). CarLotz is the used car industry’s only consignment-to-retail marketplace, designed to deliver the best deals to both sellers and buyers via its customer-friendly, low-friction platform.

  • Poshmark Inc Initiation

    William Blair & Company initiated research coverage of Poshmark, Inc. (POSH $66.74), a technology platform and social marketplace where users can buy or sell new or used clothing, shoes, and accessories using its data-driven recommendation engine to drive transactions for its sellers.

  • Beam Therapeutics Inc Initiation

    William Blair & Company initiated research coverage of Beam Therapeutics Inc. (BEAM $19.01), a gene-editing company focused on developing innovative, precision medicines for serious diseases using the company’s proprietary base editing technology.

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures